Onco Wiki / Indication

Kaposi sarcoma · line 1 · Sirolimus conversion (iatrogenic/transplant-associated Kaposi sarcoma)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy1
Trackstandard
Linked regimenREG-SIROLIMUS-KAPOSI-CONVERSION
IDIND-KAPOSI-1L-IATROGENIC-MTOR-CONVERSION
TypeIndication
Statusreviewed 2026-07-11 | pending_clinical_signoff
DiseasesDIS-KAPOSI
SourcesSRC-IARC-MONO-100B-2012 SRC-NCCN-SKIN-2025

Notes

STUB -- new TREATMENT-intent Indication for DIS-KAPOSI (v0.3 continuation). Distinct from the pre-existing PREVENTION-intent IND-CHRONIC-HHV8-PREVENTION-IMMUNE-RESTORATION -- this Indication applies to patients with a CONFIRMED Kaposi sarcoma diagnosis. Introduces new Regimen REG-SIROLIMUS-KAPOSI-CONVERSION (reuses the existing DRUG-SIROLIMUS entity; see that Regimen's notes for the CHARTER §8.3 dosing-gap disclosure). INDEPENDENT REVIEW CORRECTION (2026-07-11): an earlier draft cited SRC-NCCN-SKIN-2025 with position "supports". That source documents only basal-cell/squamous-cell skin cancer (confirmed by direct inspection of its own KB record) -- it has no bearing on transplant immunosuppression management or mTOR-inhibitor conversion. Downgraded to "context" (loose disease-level background only, matching how dis_kaposi.yaml itself cites it) rather than removed outright, since the core clinical claim (mTOR conversion for iatrogenic KS) traces directly to the authoring narrative, not to this citation. No source in this KB currently documents the transplant-immunosuppression-conversion literature specifically -- a real, disclosed evidentiary gap. Pending two-Clinical-Co-Lead signof...

Used By

Algorithms

Disease

Indication